Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

British Journal of Cancer

Volumn 87, Issue 10, 2002, Pages 1166-1172

  Dredge, K ^a   Marriott, J B ^a   Macdonald, C D ^a   Man, H W ^b   Chen, R ^b   Muller, G W ^b   Stirling, D ^b   Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CELGENE CORPORATION   (United States)

Author keywords

Anti angiogenic; IMiDs; Immunomodulatory; SeICIDs; Thalidomide analogues

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; LENALIDOMIDE; PHOSPHODIESTERASE IV INHIBITOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AORTA; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; DRUG ACTIVITY; DRUG POTENCY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; MIGRATION INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIVISION; CELL MOVEMENT; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; RATS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037021257     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600607     Document Type: Article

References (36)

1. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 35: 1827-1834
2. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NFK, Wheatly DN (2000) An in vitro model of angiogenesis: Basic features. Angiogenesis 3(4): 335-344
3. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
4. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of Thd analogues that are potent inhibitors of TNF-α. J Immunol 163: 380-386
5. D'Amato JD, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91: 4082-4085
6. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, Paparelli A, Del Tacca M (1993) Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 68: 932-938
7. Di Santo ME, Heaslip RJ (1993) Identification and stabilization of large molecular weight PDE-IVs from U397 cells. Biochem Biophys Res Comm 197: 1126-1128
8. Donovan D, Brown NJ, Bishop ET, Lewis CE (2001) Comparison of three in vitro human angiogenesis assays with capillaries formed in vivo. Angiogenesis 4(2): 113-121
9. Drinkwater SL, Smith A, Sawyer BM, Burnard KG (2002) Effect of venous ulcer exudates on angiogenesis in vitro. Br J Surg 89(6): 709-713
10. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K, Matsuno S (2000) Cancer Res 60: 1111-1116
11. Edgell CJ, McDonald CC, Graham JB (1983) Permanent cell line expressing human factor VIII-related antigen established by hybridisation. Proc Natl Acad Sci 80: 3734-3737
12. Folkman J (1971) Tumour angiogenesis: Therapeutic implications. N Engl J Med 181: 182-186
13. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL (1995) Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, chalkley count, and computer image analysis. J Pathol 177: 275-283
14. Franks L, Hemmings V (1978) A cell line from an induced carcinoma of a mouse rectum. J Pathol 124: 35-38
15. Griffioen AW, Molema G (2000) Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52: 237-268
16. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. (2000) Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950
17. Hill PA, Mitchell RL (1994) Characterisation of phosphodiesterase activity from U937 cells. FASEB J 8: A217
18. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression, and growth in tumours mediated by angiopoietins and VEGF. Science 284: 1994-1998
19. Igura K, Ohta T, Kuroda Y, Kaji K (2001) Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 171: 11-16
20. Kenyon BM, Browne F, d'Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64: 971-978
21. Liekens S, Bilsen F, De Clercq E, Priego EM, Camarasa MJ, Perez-Perez MJ, Balzarini J (2001) Anti-angiogenic activity of a novel multi-substrate analogue inhibitor of thymidine phosphorylase. FEBS 510(1-2): 83-88
22. + T cells. Clin Exp Immunol 130: 75-84
23. Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, Muller G, Shire MG, Stirling D, Dalgleish AG (1998) CC-3052: A water soluble analogue of thalidomide and potent inhibitor of activation-induced TNF-α production. J Immunol 161: 4236-4243
24. Marriott JB, Muller G, Stirling D, Dalgleish AG (2001) Immunotherapeutic and anti-tumour potential of thalidomide analogues. Expert Opin Biol Ther 1: 1-8
25. Moreira AL, Friedlander DP, Shif B, Kaplan G, Zagzag D (1999) Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neuro-Oncol 43: 109-114
26. Muller GW, Shire MG, Wong LM, Corral LG, Patterson RT, Chin Y, Stirling DI (1998) Thalidomide analogues and PDE4 inhibition. Bioorg Med Chem Lett 8: 2669-2674
27. Nicosia RF, Ottinetti A (1990) Growth of microvessels in serum-free matrix culture of rat aorta: A quantitative assay of angiogenesis in vitro. Lab Invest 63: 115-122
28. Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, Negoro S, Kunisada K, Izumi M, Nakaoka Y, Hirota H, Okabe M, Yamauchi-Takihara K, Kawase I, Kishimoto T (2002) Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem 277(8): 6676-6681
29. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B (1999) Antitumour activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
30. Small EJ, Meyer M, Marshall ME, Reyno LM, Meters FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18: 1440-1450
31. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE (1989) Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499-508
32. Stevenson DP, Collins WP, Farzaneh F, Hata K, Miyazaki K (1998) Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis. Am J Pathol 153: 1573-1578
33. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S (1994) Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell bending of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660
34. Terai Y, Abe M, Miyamoto K, Koike M, Yamasaki M, Ueda M, Sato Y (2001) Vascular smooth muscle cell growth-promoting factor/F-spondin inhibits angiogenesis via the bloackade of integrina Vb3 on vascular endothelial cells. J Cell Physiol 188: 394-402
35. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, d'Amato RJ, Folkman J (1998) Inhibition of angiogenesis in vivo by interleukin 12. Int J Cancer 78: 361-365
36. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (Second Edition). Br J Cancer 77: 1-12